RT Journal Article
SR Electronic
T1 Year-round RSV Transmission in the Netherlands Following the COVID-19 Pandemic - A Prospective Nationwide Observational and Modeling Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.10.22282132
DO 10.1101/2022.11.10.22282132
A1 Löwensteyn, Yvette N.
A1 Zheng, Zhe
A1 Rave, Neele
A1 Bannier, Michiel A.G.E.
A1 Billard, Marie-Noëlle
A1 Casalegno, Jean-Sebastien
A1 Pitzer, Virginia E.
A1 Wildenbeest, Joanne G.
A1 Weinberger, Daniel M.
A1 Bont, Louis
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/11/11/2022.11.10.22282132.abstract
AB A nationwide prospective study showed year-round RSV transmission in the Netherlands after an initial 2021 summer outbreak. The pattern was unprecedented and distinct from neighboring countries. Our dynamic simulation model suggests that this transmission pattern could be associated with waning immunity because of low RSV circulation during the COVID-19 pandemic.Competing Interest StatementLouis Bont has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. University Medical Centre Utrecht (UMCU) has received major funding (>100,000 euros per industrial partner) for investigator-initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation, Nutricia (Danone) and MeMed Diagnostics. UMCU has received major cash or in kind funding as part of the public private partnership IMI-funded RESCEU project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. University Medical Centre Utrecht has received major funding by Julius Clinical for participating in the INFORM study sponsored by MedImmune. UMCU has received minor funding for participation in trials by Regeneron and Janssen from 2015-2017 (total annual estimate less than 20,000 euros). UMCU received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer, Janssen (total annual estimate less than 20,000 euros). Louis Bont is the founding chairman of the ReSViNET Foundation. Virginia Pitzer has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements on respiratory syncytial virus. Daniel Weinberger has received consulting fees from Pfizer, Merck, GSK, Affinivax, and Matrivax for work unrelated to this manuscript and is the principal investigator on research grants from Pfizer and Merck on work unrelated to this manuscript. Zhe Zheng is expected to receive consulting fees from Pfizer for work unrelated to this manuscript. No other conflicts of interest exist. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.Funding StatementThis work was supported by ZonMw and the National Institute of Allergy and Infectious Diseases (MIDAS Program) of the U.S. National Institutes of Health under award number R01AI137093. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Research Ethics Committee Utrecht waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code to reproduce the simulation are available from GitHub (https://github.com/weinbergerlab/SPREAD.git). https://github.com/weinbergerlab/SPREAD.git